Insulin-like growth factor I (IGF-I) is a useful therapeutic agent in insulin resistant diabetes mellitus due to insulin receptor disease because of its hypoglycaemic effects through the IGF-I receptor. A girl with typical type A insulin resistant syndrome was treated with IGF-I for two years and the treatment was effective in ameliorating hyperglycaemia. Overproduction of testosterone in polycystic ovaries was aggravated with this treatment, however. Therefore, IGF-I treatment may be used for glycaemic control but with caution because of its possible side effect of aggravating hyperandrogenism in these patients.
The characteristic features of type A insulin resistant syndrome are extreme insulin resistance, acanthosis nigricans, and ovarian hyperandrogenism. The mechanism of the insulin resistance is either a defect in insulin receptor itself or postreceptor abnormality. Recently, several investigators have reported various mutations or deletions of insulin receptor gene in this disorder, [1] [2] [3] which cause decreased receptor number, decreased binding affinity, or abnormality in signal transduction due to a kinase defect. On the other hand, although it has been speculated that acanthosis nigricans and ovarian hyperandrogenism originate from secondary hyperinsulinaemia, the precise mechanism is still unclear.4
Insulin-like growth factor I (IGF-I) has growth promoting activity and also metabolic effects through the IGF-I receptor. 
Methods
The method for the 125I-insulin binding to erythrocytes, transformed lymphocytes, and cultured fibroblasts has been described by Sasaoka et al. 5 6 Surface labelling of EpsteinBarr virus transformed lymphocytes was determined by the method described previously. 7 We performed subsequent DNA analysis of insulin receptor gene by a modification of the method described by Kusukawa et al8 and examined transfection of insulin receptor c-DNA to COS7 cells according to the method of Kobayashi et al. 9 Recombinant human IGF-I was provided by the Fujisawa pharmaceutical industry (Osaka, Japan). Treatment was started at the age of 13 years after informed consent was obtained from the patient and her parents. Lyophilised IGF-I freshly dissolved in normal saline was injected subcutaneously before breakfast and supper every day. The initial dose, which was determined by the dose trial study, was 0-25 mg/kg/dose. She did not receive any other medication. Blood sampling was done on admission and thereafter every three months to evaluate her plasma glucose profile, HbA1C, fructosamine, plasma insulin, and total IGF-I. Routine haematological and biochemical examinations were also performed at the same time. Serum testosterone concentration was serially examined every four months after treatment. Height and weight were measured on each admission. A luteinising hormone releasing hormone (LH-RH) stimulation test was carried out at pretreatment and 19 months after the treatment.
Results
Insulin binding to erythrocytes, transformed lymphocytes, and cultured fibroblasts was There was another reason for selecting IGF-I as the choice for treatment of extreme insulin resistant syndrome with mild diabetes mellitus such as in our case. Namely, we expected IGF-I might improve acanthosis nigricans and ovarian hyperandrogenism by decreasing plasma insulin concentrations as it has been suggested that these features are due to hyperinsulinaemia.11 However, serum testosterone was increased by the treatment. Furthermore, it decreased in proportion to the reduced dose of IGF-I and again increased moderately as hyperinsulinaemia returned with the interruption of IGF-I treatment. These findings not only suggested that IGF-I administration could aggravate overproduction of testosterone in type A insulin receptor disease, but also supported animal experimental data that showed that IGF-I as well as insulin was capable of augmenting androgen synthesis in ovarian theca interstitial cells.'2-14 In our patient, IGF-I treatment seemed to cause a different therapeutic effect on acanthosis nigricans and hyperandrogenism. However, it was not certain whether IGF-I was directly related to these manifestations as there was no significant change in clinical features at six months after the end of the treatment.
In conclusion, IGF-I administration is effective in ameliorating hyperglycaemia in cases of type A insulin resistant syndrome, but it is important to be aware that IGF-I may aggravate hyperandrogenism in these patients.
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